FDA cited S & J International Enterprises for CGMP violations, data integrity failures, and limiting access to records during a drug inspection.
What happened
FDA inspected the drug manufacturing facility from July 17 to July 21, 2023. The agency found that the quality unit did not adequately oversee manufacturing, production records could be altered or were incomplete, laboratory preparation and raw data review were not documented, and the firm delayed or limited access to requested records. FDA said the company's response to the inspection findings was inadequate.
What FDA found
The quality control unit did not adequately oversee manufacturing or ensure that drugs met specifications for identity, strength, quality, and purity; production staff could alter master batch records, laboratory sample preparation was not documented, and raw analytical data was not reviewed before release.
21 CFR 211.22Batch production and control records were incomplete because production data were kept on laminated sheets with erasable markers and permanent versions could not be provided.
21 CFR 211.188The firm delayed and limited access to or copying of requested records during the inspection, including labeling and laboratory non-conformance logs.
section 501(j) of the FD&C Act, 21 U.S.C. 351(j)Because methods, facilities, or controls did not conform to CGMP, the drug products were adulterated.
section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also asks for a comprehensive quality unit assessment, documentation and data integrity remediation, and recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy finished drug products from this contract manufacturer
- U.S. importers and distributors of drugs made in Thailand
- quality teams relying on S & J's batch records or laboratory data
This is a summary. Read the original letter on fda.gov.